Pete Schmidt

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers

B. Gunn, L. Walker, E. Krauland, 2022, Science Translational Medicine.

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron

M. Dimopoulos, N. Nikolaev, M. Ison, 2023, Open forum infectious diseases.

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults

F. Engler, Ed Campanaro, Yong Li, 2023, Infectious Diseases and Therapy.

226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study

F. Engler, Ed Campanaro, A. Copans, 2022, Open Forum Infectious Diseases.

633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-1

Anita F. Das, F. Engler, P. Ambrose, 2021, Open Forum Infectious Diseases.

Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)

M. Ison, E. Hershberger, L. Connolly, 2023, Open forum infectious diseases.